Search

South Dakota Rural Health Transformation RFPs Released

The State of South Dakota has released the first round of Requests for Proposals (RFPs) for its Rural Health Transformation initiative. These RFPs aim to strengthen rural healthcare systems through digital health modernization, coordinated care, and project management, with funding provided by HB 1044.

Oregon State Health Improvement Plan 2025-2029 Launched

The Oregon Health Authority has launched its 2025-2029 State Health Improvement Plan (SHIP), outlining four key priorities for the state's public health system. The plan aligns with the OHA's strategic goals and aims to reduce health inequities by 2030.

FDA Guidance on Progestins as Endocrine Disruptors

The FDA has issued new guidance concerning progestins and their potential role as endocrine disruptors. This document outlines the agency's current thinking and provides information relevant to manufacturers and public health authorities.

FDA Progestins Classification and Pharmacology

The Food and Drug Administration (FDA) has published a document detailing the classification and pharmacology of progestins. This guidance provides information for manufacturers and pharmaceutical companies regarding these substances.

Hormonal Contraceptive Eligibility for Women at High HIV Risk

The FDA has issued draft guidance regarding the eligibility of hormonal contraceptives for women at high risk of HIV. This guidance aims to clarify recommendations and ensure appropriate access to contraceptive methods while considering HIV prevention strategies.

FDA Variance Approval for North Bay Productions

The FDA has issued a variance approval letter to North Bay Productions. This document, originating from the CDRH, signifies an approval related to a specific variance request.

Draft Labeling for Atomoxetine HCL Solution

The FDA has posted draft labeling for Atomoxetine HCL Solution for public comment. This document outlines proposed changes to the drug's labeling, which will impact manufacturers and potentially healthcare providers.

FDA Natural Family Planning Review

The FDA has posted a review concerning Natural Family Planning methods. This document provides updated information and guidance related to these methods.

FDA Document on Ovarian Cancer Risk Factors

The FDA has released a document concerning risk factors associated with ovarian cancer. This guidance is intended for manufacturers and healthcare providers involved in the pharmaceutical and medical device sectors.

ATSDR Tox Profile for CDDs

The Agency for Toxic Substances and Disease Registry (ATSDR) has posted a Toxicological Profile for CDDs. This document provides health information concerning environmental agents and is intended for public health and environmental professionals.